Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
11 p, 2.1 MB Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma / Ito, Masaoki (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Codony-Servat, Jordi (Institut Universitari Dexeus) ; Giménez-Capitán, Ana (Institut Universitari Dexeus) ; Serra-Mitjans, Mireia (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Pérez-Ochoa, Francisco (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Llige, David (Institut Germans Trias i Pujol) ; Chaib, Imane (Institut Germans Trias i Pujol) ; Rami-Porta, Ramon (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Obiols, Carme (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Call, Sergi (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Iglesias, Manuela (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Belda, José (Belda Sanchis) (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Tarroch-Sarasa, Xavier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Karachaliou, Niki (Institut Universitari Dexeus) ; Molina-Vila, Miguel Angel (Institut Universitari Dexeus) ; Okada, Morihito (Hiroshima University. Department of Surgical Oncology) ; Rosell, Rafael (Institut Germans Trias i Pujol)
EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be predictive in patients positive with resected EGFR mutation versus patients with EGFR wild-type LUAD. [...]
2020 - 10.1016/j.jtocrr.2020.100084
JTO Clinical and Research Reports, Vol. 1 Núm. 4 (august 2020)  
2.
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony-Servat, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cuatrecasas, Miriam ; Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Montironi, Carla (Hospital Clínic i Provincial de Barcelona) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Marín Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Horndler, Carlos (Hospital Universitario Miguel Servet (Saragossa)) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ; Reig, Oscar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Victoria, Iván (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Gaba, Lydia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Fernández-Martos, Carlos (Fundació Institut Valencià d'Oncologia) ; Feliu, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital Universitario de Móstoles (Madrid)) ; Gallego, Javier (Hospital General Universitario de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Universitat Autònoma de Barcelona
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
3.
12 p, 1.4 MB Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC / Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ; Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ; Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ; Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Drozdowskyj, Ana (Pivotal, Madrid) ; Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ; Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Cardona Zorrilla, Andrés Felipe (Clinica del Country, Bogotá) ; Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Jose Miguel Sanchez (Hospital Universitario de la Princesa (Madrid)) ; Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ; Teixido, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ; Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ; Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ; Aguirre, Itziar de (Institut Germans Trias i Pujol) ; Queralt, C (Institut Germans Trias i Pujol) ; Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol) ; Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ; Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ; Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Bivona, Trever G. (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12  
4.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramírez, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports (Nature Publishing Group), Vol. 7 (December 2015)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.